The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer
Abstract
Background: Although some retrospective studies have suggested the value of adjuvant therapy, no recommended standard exists in bile duct cancer. The aim of this study was to test the hypothesis that adjuvant gemcitabine chemotherapy would improve survival probability in resected bile duct cancer. Methods: This was a randomized phase III trial. Patients with resected bile duct cancer were assigned randomly to gemcitabine and observation groups, which were balanced with respect to lymph node status, residual tumour status and tumour location. Gemcitabine was given intravenously at a dose of 1000 mg/m2, administered on days 1, 8 and 15 every 4 weeks for six cycles. The primary endpoint was overall survival, and secondary endpoints were relapse-free survival, subgroup analysis and toxicity. Results: Some 225 patients were included (117 gemcitabine, 108 observation). Baseline characteristics were well balanced between the gemcitabine and observation groups. There were no significant differences in overall survival (median 62·3 versus 63·8 months respectively; hazard ratio 1·01, 95 per cent c.i. 0·70 to 1·45; P = 0·964) and relapse-free survival (median 36·0 versus 39·9 months; hazard ratio 0·93, 0·66 to 1·32; P = 0·693). There were no survival differences between the two groups in subsets stratified by lymph node status and margin status. Although haematological toxicity occurred frequently in the gemcitabine group, most toxicities were transient, and grade 3/4 non-haematological toxicity was rare. Conclusion: The survival probability in patients with resected bile duct cancer was not significantly different between the gemcitabine adjuvant chemotherapy group and the observation group. Registration number: UMIN 000000820 (http://www.umin.ac.jp/).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., et al. (2007) · JAMA · doi:10.1001/jama.297.3.267 · Cited by 2,419
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Uesaka, K., Boku, N., Fukutomi, A., Okamura, Y., Konishi, M., Matsumoto, I., Kaneoka, Y., Shimizu, Y., Nakamori, S., Sakamoto, H., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30583-9 · Cited by 1,115
Self-citationGuidelines for the diagnosis and treatment of cholangiocarcinoma: an update
Khan, S. A., Davidson, B. R., Goldin, R. D., Heaton, N., Karani, J., Pereira, S. P., Rosenberg, W. M. C., Tait, P., Taylor-Robinson, S. D., Thillainayagam, A. V., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301748 · Cited by 797
Adjuvant Therapy in the Treatment of Biliary Tract Cancer: A Systematic Review and Meta-Analysis
Horgan, A. M., Amir, E., Walter, T., & Knox, J. J. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.5381 · Cited by 716
Nagino, M., Ebata, T., Yokoyama, Y., Igami, T., Sugawara, G., Takahashi, Y., & Nimura, Y. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e3182708b57 · Cited by 656
Self-citationStudy Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract, Takada, T., Amano, H., Yasuda, H., Nimura, Y., Matsushiro, T., Kato, H., Nagakawa, T., & Nakayama, T. (2002) · Cancer · doi:10.1002/cncr.10831 · Cited by 631
Self-citationUeno, H., Kosuge, T., Matsuyama, Y., Yamamoto, J., Nakao, A., Egawa, S., Doi, R., Monden, M., Hatori, T., Tanaka, M., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605256 · Cited by 439
Self-citationHilar cholangiocarcinoma: expert consensus statement
Mansour, J. C., Aloia, T. A., Crane, C. H., Heimbach, J. K., Nagino, M., & Vauthey, J.-N. (2015) · HPB · doi:10.1111/hpb.12450 · Cited by 414
Self-citationHepatectomy With Portal Vein Resection for Hilar Cholangiocarcinoma: Audit of 52 Consecutive Cases
Ebata, T., Nagino, M., Kamiya, J., Uesaka, K., Nagasaka, T., & Nimura, Y. (2003) · Annals of Surgery · doi:10.1097/01.sla.0000094437.68038.a3 · Cited by 328
Self-citationStein, A., Arnold, D., Bridgewater, J., Goldstein, D., Jensen, L. H., Klümpen, H.-J., Lohse, A. W., Nashan, B., Primrose, J., Schrum, S., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1498-0 · Cited by 238
Ebata, T., Yokoyama, Y., Igami, T., Sugawara, G., Takahashi, Y., Nimura, Y., & Nagino, M. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e31826029ca · Cited by 203
Self-citationAdjuvant capecitabine for biliary tract cancer: The BILCAP randomized study.
Primrose, J. N., Fox, R., Palmer, D. H., Prasad, R., Mirza, D., Anthoney, D. A., Corrie, P., Falk, S., Wasan, H. S., Ross, P. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4006 · Cited by 190
Recurrence after resection with curative intent for distal cholangiocarcinoma
Komaya, K., Ebata, T., Shirai, K., Ohira, S., Morofuji, N., Akutagawa, A., Yamaguchi, R., Nagino, M., Aoba, T., Kaneoka, Y., et al. (2017) · British journal of surgery · doi:10.1002/bjs.10452 · Cited by 129
Self-citationEdeline, J., Bonnetain, F., Phelip, J., Watelet, J., Hammel, P. R., Joly, J., Abdelghani, M. B., Rosmorduc, O., Bouhier‐Leporrier, K., Jouve, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.225 · Cited by 110
Disease recurrence patterns after R0 resection of hilar cholangiocarcinoma
Kobayashi, A., Miwa, S., Nakata, T., et al. (2009) · British journal of surgery · doi:10.1002/bjs.6788 · Cited by 109
A Step Forward in the Treatment of Advanced Biliary Tract Cancer
Wolpin, B. M., & Mayer, R. J. (2010) · New England Journal of Medicine · doi:10.1056/nejme1001183 · Cited by 44
Fujiwara, Y., Kobayashi, S., Nagano, H., Kanai, M., Hatano, E., Toyoda, M., Ajiki, T., Takashima, Y., Yoshimura, K., Hamada, A., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143072 · Cited by 18
Self-citation
Cited by
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Banales, J. M., Marin, J. J. G., Lamarca, A., Rodrigues, P. M., Khan, S. A., Roberts, L. R., Cardinale, V., Carpino, G., Andersen, J. B., Braconi, C., et al. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0310-z · Cited by 2,411
Primrose, J. N., Fox, R. P., Palmer, D. H., Malik, H. Z., Prasad, R., Mirza, D., Anthony, A., Corrie, P., Falk, S., Finch-Jones, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30915-x · Cited by 1,273
Valle, J. W., Kelley, R. K., Nervi, B., Oh, D.-Y., & Zhu, A. X. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00153-7 · Cited by 1,043
Brindley, P. J., Bachini, M., Ilyas, S. I., Khan, S. A., Loukas, A., Sirica, A. E., Teh, B. T., Wongkham, S., & Gores, G. J. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00300-2 · Cited by 841
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Vogel, A., Bridgewater, J., Edeline, J., Kelley, R. K., Klümpen, H. J., Malka, D., Primrose, J. N., Rimassa, L., Stenzinger, A., Valle, J. W., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.506 · Cited by 718
Metadata
- Authors
- Ebata, T., Hirano, S., Konishi, M., Uesaka, K., Tsuchiya, Y., Ohtsuka, M., Kaneoka, Y., Yamamoto, M., Ambo, Y., Shimizu, Y., Ozawa, F., Fukutomi, A., Ando, M., Nimura, Y., Nagino, M., Nakamori, S., Ajiki, T., Baba, H., Yamaguchi, R., Kawai, M., Nagano, H., Miura, F., Arai, T., Nishiwaki, Y., Kawasaki, S., Shinchi, H., Shimoda, M., Yamamoto, Y., Endo, I., Isaji, S., Otsubo, T., Ishihara, S., Takahara, T., Shimada, M., Unno, M., Imamura, M., Ohkochi, N., Murakami, Y., Fujimoto, J., Ikuta, S., Fujino, Y., Uebayashi, M., Ishiyama, S., Takakura, N., Kumamoto, Y., Kato, T., Yoshioka, I., Uemoto, S., & Yanaga, K.
- Venue
- British Journal of Surgery
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-02
- Volume
- 105
- Issue
- 3
- Pages
- 192-202
- ISSN
- 0007-1323 (ISSN-L)
- 1365-2168
- OpenAlex
- W2790277876
- Cited by
- 397
- References
- 18
- FWCI
- 36.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.